<?xml version='1.0' encoding='utf-8'?>
<document id="26231433"><sentence text="Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics." /><sentence text="Mavoglurant (MVG) is an antagonist at the metabotropic glutamate receptor-5 currently under clinical development at Novartis Pharma AG for the treatment of central nervous system diseases"><entity charOffset="55-64" id="DDI-PubMed.26231433.s2.e0" text="glutamate" /></sentence><sentence text=" The aim of this study was to develop and optimise a population whole-body physiologically-based pharmacokinetic (WBPBPK) model for MVG, to predict the impact of drug-drug interaction (DDI) and age on its pharmacokinetics" /><sentence text=" In a first step, the model was fitted to intravenous (IV) data from a clinical study in adults using a Bayesian approach" /><sentence text=" In a second step, the optimised model was used together with a mechanistic absorption model for exploratory Monte Carlo simulations" /><sentence text=" The ability of the model to predict MVG pharmacokinetics when orally co-administered with ketoconazole in adults or administered alone in 3-11 year-old children was evaluated using data from three other clinical studies"><entity charOffset="91-103" id="DDI-PubMed.26231433.s6.e0" text="ketoconazole" /></sentence><sentence text=" The population model provided a good description of both the median trend and variability in MVG plasma pharmacokinetics following IV administration in adults" /><sentence text=" The Bayesian approach offered a continuous flow of information from pre-clinical to clinical studies" /><sentence text=" Prediction of the DDI with ketoconazole was consistent with the results of a non-compartmental analysis of the clinical data (threefold increase in systemic exposure)"><entity charOffset="28-40" id="DDI-PubMed.26231433.s9.e0" text="ketoconazole" /></sentence><sentence text=" Scaling of the WBPBPK model allowed reasonable extrapolation of MVG pharmacokinetics from adults to children" /><sentence text=" The model can be used to predict plasma and brain (target site) concentration-time profiles following oral administration of various immediate-release formulations of MVG alone or when co-administered with other drugs, in adults as well as in children" /><sentence text="" /></document>